You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 7, 2025

Details for Patent: 9,255,087


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,255,087 protect, and when does it expire?

Patent 9,255,087 protects ROZLYTREK and is included in one NDA.

This patent has thirty-six patent family members in twenty-seven countries.

Summary for Patent: 9,255,087
Title:Substituted indazole derivatives active as kinase inhibitors
Abstract: Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like cancer.
Inventor(s): Lombardi Borgia; Andrea (Paullo, IT), Menichincheri; Maria (Milan, IT), Orsini; Paolo (Legnano, IT), Panzeri; Achille (Merate, IT), Perrone; Ettore (Boffalora Sopra Ticino, IT), Vanotti; Ermes (Milan, IT), Nesi; Marcella (Saronno, IT), Marchionni; Chiara (Milan, IT)
Assignee: NERVIANO MEDICAL SCIENCES S.R.L. (Nerviano (MI), IT)
Application Number:14/534,617
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope and Claims of United States Patent 9,255,087

Introduction

United States Patent 9,255,087, titled "Substituted indazole derivatives active as kinase inhibitors," is a patent that covers a specific class of chemical compounds and their pharmaceutical applications. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this patent.

Patent Overview

Publication Details

  • Publication Number: US9255087B2
  • Authority: United States
  • Prior Art Date: The patent has several priority dates, but the key date for prior art consideration would be related to the earliest filing dates of the provisional and international applications that led to this patent[4].

Invention Description

The patent describes substituted indazole derivatives and their pharmaceutically acceptable salts, which are active as kinase inhibitors. Kinase inhibitors are crucial in the treatment of various diseases, including cancer, by inhibiting the activity of kinases, which are enzymes involved in cell signaling pathways.

Claims Analysis

Independent Claims

The patent includes several independent claims that define the scope of the invention. These claims typically describe the chemical structure of the substituted indazole derivatives, their pharmaceutical compositions, and methods of use. For example:

  • Claim 1 might describe the general chemical formula of the substituted indazole derivatives.
  • Claim 2 could specify particular substituents on the indazole ring.
  • Claim 3 might cover pharmaceutical compositions containing these compounds.
  • Claim 4 could outline methods for treating diseases using these kinase inhibitors[4].

Dependent Claims

Dependent claims further narrow down the scope of the independent claims by adding additional limitations. These could include specific types of kinases targeted, dosages, or specific disease conditions treated.

Patent Scope and Coverage

Chemical Structure

The patent specifically covers substituted indazole derivatives with particular functional groups. This includes variations such as different methyl, benzamide, and other substituents attached to the indazole ring. The scope is defined by the chemical formulas and structural descriptions provided in the patent specification[4].

Pharmaceutical Applications

The patent also covers the use of these compounds as kinase inhibitors in pharmaceutical compositions. This includes formulations, dosages, and methods of administration for treating various diseases, particularly those involving abnormal kinase activity.

Patent Landscape Analysis

Competitor Landscape

A patent landscape analysis helps in understanding the competitive environment surrounding the patented technology. For US9255087B2, this would involve identifying other patents and patent applications related to kinase inhibitors, particularly those focusing on indazole derivatives.

  • Saturation Analysis: A full patent landscape analysis would reveal the level of saturation in the technology area. If the area is highly saturated, it might indicate a need to pivot to newer inventive spaces to avoid infringement and maintain competitiveness[3].

  • Time-Slicing: Analyzing the patent filings over time can show trends and shifts in research focus. For example, if there is a decrease in patent filings related to indazole derivatives after a certain year, it could indicate a move away from this technology area[3].

Prior Art and Citation Analysis

  • Common Citation Document (CCD): Using tools like the CCD, one can consolidate prior art citations from multiple patent offices to understand the global landscape and potential challenges to the patent's validity[1].

  • Office Actions: Reviewing office actions and citations from other patent applications can provide insights into potential weaknesses or areas of contention in the patent claims.

Strategic Insights

Business and R&D Decisions

A comprehensive patent landscape analysis can help business and R&D management make informed decisions about investing in this technology area.

  • Pivot Strategies: If the analysis shows high saturation and limited room for innovation, it might be wise to pivot to newer technology areas to maintain a competitive edge[3].

  • Licensing and Collaboration: Understanding the competitive landscape can also help in identifying potential partners for licensing or collaboration, which could be beneficial for further development and commercialization.

Legal and Regulatory Considerations

Patent Validity and Enforcement

The validity and enforceability of the patent can be affected by various legal and regulatory factors.

  • Inter Partes Review (IPR): The patent could be subject to IPR proceedings, as seen in other cases, where the validity of the claims is challenged based on prior art and other grounds[5].

  • Small Claims Patent Court: Proposals for a small claims patent court could potentially impact how disputes related to this patent are resolved, making it easier and less costly to enforce or challenge patent rights[2].

Key Takeaways

  • Specific Claims: The patent specifically covers substituted indazole derivatives and their use as kinase inhibitors.
  • Competitive Landscape: A thorough patent landscape analysis is crucial for understanding the competitive environment and making strategic decisions.
  • Legal Considerations: The patent's validity and enforceability can be influenced by prior art, office actions, and legal proceedings.
  • Business Decisions: The analysis can guide business and R&D decisions on whether to invest in this technology area or pivot to newer spaces.

FAQs

What is the main subject of United States Patent 9,255,087?

The main subject of US9255087B2 is substituted indazole derivatives and their use as kinase inhibitors in pharmaceutical applications.

How can a patent landscape analysis help in understanding this patent?

A patent landscape analysis helps in identifying the competitive environment, saturation levels in the technology area, and trends over time, which can guide business and R&D decisions.

What are the key components of the claims in this patent?

The claims include descriptions of the chemical structure of the substituted indazole derivatives, pharmaceutical compositions, and methods of use for treating diseases.

How might the validity of this patent be challenged?

The validity of the patent could be challenged through inter partes review (IPR) proceedings based on prior art and other grounds.

What is the significance of the Common Citation Document (CCD) in patent analysis?

The CCD consolidates prior art citations from multiple patent offices, providing a comprehensive view of the global landscape and potential challenges to the patent's validity.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 9,255,087

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-001 Aug 15, 2019 RX Yes No 9,255,087 ⤷  Subscribe TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION ⤷  Subscribe
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-001 Aug 15, 2019 RX Yes No 9,255,087 ⤷  Subscribe TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER ⤷  Subscribe
Genentech Inc ROZLYTREK entrectinib CAPSULE;ORAL 212725-002 Aug 15, 2019 RX Yes Yes 9,255,087 ⤷  Subscribe TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,255,087

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
07112881Jul 20, 2007

International Family Members for US Patent 9,255,087

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2176231 ⤷  Subscribe 132020000000164 Italy ⤷  Subscribe
European Patent Office 2176231 ⤷  Subscribe LUC00191 Luxembourg ⤷  Subscribe
European Patent Office 2176231 ⤷  Subscribe 122020000081 Germany ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.